Literature DB >> 18666038

Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.

Diego Ripamonti1, Franco Maggiolo.   

Abstract

Tibotec BVBA is developing the diarylpyrimidine rilpivirine, a second-generation non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection. A phase III trial of rilpivirine in HIV-infected, treatment-naive indivuduals is underway and is to be completed by August 2010.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18666038

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  4 in total

1.  Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.

Authors:  Xingtao Tian; Bingjie Qin; Zhiyuan Wu; Xiaofeng Wang; Hong Lu; Susan L Morris-Natschke; Chin Ho Chen; Shibo Jiang; Kuo-Hsiung Lee; Lan Xie
Journal:  J Med Chem       Date:  2010-11-04       Impact factor: 7.446

2.  Confocal fluorescence microscopy: An ultra-sensitive tool used to evaluate intracellular antiretroviral nano-drug delivery in HeLa cells.

Authors:  Subhra Mandal; You Zhou; Annemarie Shibata; Christopher J Destache
Journal:  AIP Adv       Date:  2015-07-08       Impact factor: 1.548

3.  Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.

Authors:  P Fletcher; S Harman; H Azijn; N Armanasco; P Manlow; D Perumal; M-P de Bethune; J Nuttall; J Romano; R Shattock
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

4.  Elucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulations.

Authors:  Anthony Ivetac; J Andrew McCammon
Journal:  J Mol Biol       Date:  2009-03-24       Impact factor: 5.469
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.